Releases

News

Releases

29. June, 2021

Cessatech announces new Chairman of the Board – getting ready for the pivotal studies

  The Board of Directors has appointed Adam Steensberg as new Chairman of the...

Read more

Releases

31. May, 2021

Last subject dosed in bioavailability trial 0204 of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...

Read more

Releases

14. May, 2021

Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....

Read more

Releases

19. April, 2021

First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Releases

24. March, 2021

Cessatech reports first subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...

Read more

Releases

9. March, 2021

Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial

CFI.co – a journal and online resource reporting on business, economics and finance –...

Read more

Releases

4. March, 2021

Favourable data from the Registry Safety Study

First major milestone reached: Data from the Registry Safety Study (0203) indicates a favourable...

Read more

Releases

11. February, 2021

Year-end report Q4-2020 – on track and accelerating clinical activities

Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting...

Read more

Releases

21. January, 2021

Supporting ‘Save the Children’

Cessatech has entered a corporate sponsorship with Save the Children. We want to make...

Read more

Releases

27. November, 2020

Cessatech’s IPO of units significantly oversubscribed

Subscribed to DKK 107 million, corresponding to a subscription ratio of approx. 680 percent....

Read more

Releases

6. November, 2020

Approval for IPO listing

Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...

Read more

Releases

18. August, 2020

Strong profiles to the Board

The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations

Read more

Want to see all releases?

To see all releases including those not listed here, go to our filings and reports.

Stay up to date!

Subscribe and get notified on Cessatech's latest news.